Skip to main content
BBC NEWS / HEALTH
Graphics VersionBBC Sport Home
News Front Page | Africa | Americas | Asia-Pacific | Europe | Middle East | South Asia | UK | Business | Health | Science & Environment | Technology | Entertainment | Also in the news | Have Your Say |
Health Contents:  Medical notes

Monday, 26 June 2006, 09:53 GMT 10:53 UK

Mesothelioma drug blocked for NHS

Lung x-ray A drug for the asbestos-linked cancer mesothelioma has been blocked for widespread use by the NHS in England and Wales.

The National Institute for Health and Clinical Excellence (NICE) decided Alimta should only be recommended for use in new or ongoing clinical trials.

NICE concluded there was not enough evidence the drug was better than cheaper treatments.

However, critics said some patients would be left worse off.

"This treatment does not save lives, but it can prolong the lives of patients and also improve the quality of the time they have left"
Dr Joanna Nakielny

Professor Nick Thatcher, specialist lung consultant at the Christie Hospital NHS Trust in Manchester, said: "This decision, if upheld, will remove a very useful treatment option for patients with this resistant cancer.

"It is contrary to the scientific evidence and is purely based on the value Nice place on a person's life."

Workplace exposure

Mesothelioma is a type of cancer affecting the mesothelial cells, which cover the outer surface of most of the body's internal organs.

It most often affects the lining of the lungs and about nine out of 10 cases are linked to exposure to asbestos.

Although the use of asbestos was banned in the UK in 1999, it is predicted that 65,000 people will develop mesothelioma as a result of previous exposure.

There is no cure for the disease, but Alimta, known technically as pemetrexed disodium, is used to reduce symptoms. The drug costs about £8,000 for each patient.

Eli Lilly, which manufactures the drug, said it will appeal against the decision.

It said it will encourage the use of other, unlicensed treatments which have not been assessed for use.

Dr Joanna Nakielny, medical director of Lilly UK, said: "This is a major blow for patients with mesothelioma, many of whom were unwittingly exposed to asbestos in their working lives making submarines, ships, boilers and trains.

"This treatment does not save lives, but it can prolong the lives of patients and also improve the quality of the time they have left."



E-mail this to a friend
Related to this story:
'A silent dust death sentence' (30 Jan 04 |  Scotland )
Asbestos cancer victims 'ignored' (09 Mar 05 |  Health )
'Asbestos cancer killed my husband' (09 Mar 05 |  Health )
West 'facing asbestos epidemic' (30 Jan 04 |  Health )
Asbestos disease (08 Feb 03 |  A-B )

RELATED INTERNET LINKS
Mesothelioma UK
British Lung Foundation
NICE
Eli Lilly
The BBC is not responsible for the content of external internet sites



SEARCH BBC NEWS: 

News Front Page | Africa | Americas | Asia-Pacific | Europe | Middle East | South Asia | UK | Business | Health | Science & Environment | Technology | Entertainment | Also in the news | Have Your Say |
Health Contents:  Medical notes

NewsWatch | Notes | Contact us | About BBC News | Profiles | History

^ Back to top | BBC Sport Home | BBC Homepage | Contact us | Help | ©